Miles Standish | British Wire Exclusive
In the gilded corridors of Silicon Valley and the hushed clinics of Zurich, a new kind of wealth is being engineered: biological immortality. While the rest of the world grapples with ageing populations and creaking healthcare systems, a handful of billionaires are pouring fortunes into genomic longevity tech. The promise is seductive: extend human lifespan by decades, perhaps centuries. But the concern no one is raising is that this technology is not merely a luxury; it is the harbinger of a permanent biological class divide.
The science is dazzling. CRISPR gene editing, telomere lengthening, senolytic drugs that purge zombie cells. Companies like Altos Labs, backed by Jeff Bezos and Yuri Milner, are on a quest to reprogram cells to reverse ageing. They have recruited Nobel laureates. The aim, according to leaked documents, is to achieve “biological rejuvenation” within a decade. The cost of these treatments, when they go mainstream? Estimates range from £1 million to £10 million per person. Per year. This is not healthcare. This is a membership fee for a new species.
Consider the structural failure. The NHS, already stretched, cannot afford basic cancer drugs. Yet the wealthy will soon have access to therapies that could keep them biologically 30 for a century. The secondary consequence is stark: those who can pay will not only outlive the poor but will also outcompete them. Imagine a CEO who remains mentally sharp and physically robust at 150, while their workforce ages and dies. The power imbalance is absolute.
Critics argue that costs will fall, as with mobile phones. But biology does not obey Moore’s Law. The complexity of personalised genomic medicine means that marginal costs stay high. Moreover, the patents are locked in private hands. The intellectual property for key longevity genes is owned by a single company, Gero LLC. They have no incentive to license cheaply. The result: a bottleneck controlled by the ultra-rich.
The British scientific establishment is complicit. The UK’s Biobank, a massive genomic database, is being mined by private firms to identify ageing targets. Publicly funded research is being funnelled into commercial applications. The Wellcome Trust, the UK’s largest charity, has invested heavily in longevity startups. Their justification: better health for all. But the price tag tells a different story.
What of the ethical implications? The Labour MP for Hackney, Dr. Sarah Jones, told The British Wire: “We are sleepwalking into a society where death itself is privatised. The right to live longer will become a privilege, not a right. This is the ultimate inequality.” Dr. Jones has called for a moratorium on commercial longevity trials until a public framework is established. Her bill has no support. The science lobby is too powerful.
There is a hidden cost: resource depletion. Longer lives mean more consumption. The carbon footprint of a 200-year-old billionaire is astronomical. Yet no environmental impact assessment has been conducted. The Treasury remains silent. The government is seduced by the tax revenue from these bio-tech hubs.
Miles Standish, the geneticist who broke the story of the 23andMe data leak, warns: “We are creating a biological aristocracy. The rich will not just own the means of production; they will own the means of survival. This is not science fiction. It is happening now in labs in Cambridge and Palo Alto.”
As the first “longevity patients” emerge from clinics with rejuvenated immune systems, the rest of us are left ageing in real time. The clock ticks faster for those who cannot pay. The genomic divide is not coming. It is here.
